Veradermics
MANEVeradermics is a late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for highly prevalent aesthetic and dermatological conditions.
Earnings
Next report
Nov 10, 2026 (in 2 months)Financials
Q1 2026Competitors
By market cap
By revenue growth
Profile
Veradermics is a late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for highly prevalent aesthetic and dermatological conditions. The company's primary focus is addressing Pattern Hair Loss (PHL) through a proprietary extended-release oral formulation designed to improve efficacy and safety over existing treatments. Their lead candidate aims to provide a non-hormonal, convenient alternative for both men and women in the underserved hair restoration market.
A late-stage clinical developer seeking to be the first to market with an FDA-approved oral, non-hormonal therapy for PHL.
FAQ
- What is Veradermics's market cap?
- Veradermics (MANE) has a market capitalization of $4.3B and trades on XNYS.
- Who are Veradermics's competitors?
- Veradermics's key competitors include Hims & Hers Health, Inc., Johnson & Johnson, Organon & Co., and others. These companies compete in similar markets and product categories.
- Where is Veradermics headquartered?
- Veradermics is headquartered in United States of America. It has been publicly traded since 2026.